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Abstracts / Biol Blood Marrow Transplant 19 (2013) S129eS149S130microangiopathy in the setting of candidemia. The 100-day
transplant-related mortality rate was 0% and one patient
died 5 months after ASCT due to neurological complications
without evidence of lymphoma. At a median follow-up of
399 days (range 54-705 days), only one patient, who had
multiply relapsed cutaneous and CNS large cell lymphoma,
had relapsed disease, and only one patient has died. Three
patients had optional lumbar punctures performed 24-36
hours after the ﬁrst dose of high-dose R to determine CSF
levels of R. In those patients, R was present in the lumbar CSF
at concentrations of 343-498 ng/ml. CSF rituximab levels
were about 0.1% of simultaneously obtained serum concen-
trations. For patients with CNS involvement by NHL,
a regimen of high-dose R with high-dose cytarabine for stem
cell mobilization followed by high-dose R with TBC autolo-
gous stem cell transplantation is feasible. Concentrations of R
measured in the CSF are about 0.1% of that achieved in the
peripheral blood, demonstrating limited penetration past the
blood-brain-barrier. High-dose rituximab in combination
with TBC followed by ASCT shows encouraging clinical
activity and merits further study in patients with CNS NHL.38
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Engraftment syndrome (ES) is an increasingly recognized
complication of AHCT. The clinical features consist of peri-
engraftmentnon-infectious fever, skin rash, diarrhea, hepato-
renal dysfunction or capillary leak. In severe cases, ES is more
analogous to autologous graft-versus host disease (AGVHD).
In this study, we analyze a cohort of 584 consecutive AHCT
recipients for multiple myeloma (MM) or lymphoma at our
center between 2002 and 2010 to determine risk factors asso-
ciated with ES/AGVHD. Median follow-up was 49 months. To
our knowledge, this is the largest series to report on this topic.
The median age was 57 yrs with 355 males. The under-
lying disease was MM in 71% (n¼415); non-Hodgkin
lymphoma (NHL) in 20% (n¼116); and Hodgkin lymphoma
(HL) in 9% (n¼54).
Patients were identiﬁed with ES according to Maiolino
and Spitzer criteria. A total of 131 patients (22%) developed
ES (n¼104) or biopsy proven AGVHD (n¼27). Onset of clinical
ES/AGVHD was between 3 days prior and up to 10 days after
neutrophil engraftment; at a median of 12 days after AHCT.
Clinical features were fever (90%), skin rash (50%), diarrhea
(68%) and LFT abnormalities (23%). The majority (93%) were
treated with corticosteroids, achieving a complete response.
The median duration of steroids was 12 (2-151) days. Seven
patients required additional immunosuppressive treatment.
Six deaths were attributable to ES/AGVHD. Patients with ES
had longer hospital stays with a median admission of 15 days
in those without ES/AGVHD (7-58) and 17 days (12-157) in
those with ES/AGVHD (p<0.001).
By univariate analysis, ES/AGVHD was more associated
with MM and increasing patient age. Multivariate analyses
were performed stratiﬁed by disease type MM or lymphoma.
ES was signiﬁcantly more common after 2005 in the era of
novel anti-myeloma agents with ES/AGVHD only occurring in7.5% before 2005 and in 22.6% during and after 2005
(p0.001).
In multivariate models, NHL/HL was associated with
lower risk of developing ES/AGVHD (HR¼0.36, P ¼ .0003)
while age >60 yrs was associated with higher risk (HR ¼
1.94; P ¼ .001). Considering MM patients only, pre-AHCT
exposure to Lenalidomide (HR¼1.89; P¼ .005) or Bortezomib
(HR¼2.6;P < .0001) and age >60 yrs (HR¼ 2; P ¼ .001) were
strongly associated with ES/AGVHD. There was no difference
in TRM, relapse, PFS or OS between the two groups sug-
gesting a lack of graft-versus-myeloma effect with ES/
AGVHD.
In conclusion, these data demonstrate that the increasing
incidence of ES/AGVHD in recent years maybe associated
with novel agent induction in MM. Novel agent induction
may affect T cell subpopulations in the infused graft capable
of mediating ES/AGVHD.
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Although, MM remains the most common indication for
ASCT in the US, a controversy exists about the timing of ASCT.
Since earlyASCT (eASCT) versus delayedASCT (dASCT) results
in similar progression free survival (PFS) and overall survival
(OS), economic assessment of both strategies would help in
MM treatment paradigm. A decision tree was developed to
compare the outcomes of ASCT in newly diagnosed trans-
plant eligible MM patients after chemotherapy with lenali-
domide. The survival data was obtained from our published
data on eASCT versus dASCT in MM patients who underwent
initial therapy with dexamethasone + immunomodulatory
agents (IMiDs). The initial decision node on the decision tree
model was dichotomized based on the cutoff of 12 months
(m) for eASCT versus dASCT. The probabilities of events
during the length of follow up (60m) period which formed
our base case (BC) are: (a) eASCT cohort: IMiD for median of
6m> ASCT>median 30m to relapse (and drug free interval)
>median therapy of 24m for relapsedMM; (b) dASCTcohort:
Abstracts / Biol Blood Marrow Transplant 19 (2013) S129eS149 S131Median initial therapy for 36m > ASCT > median 24m to
relapse (and drug free interval).
The cost data for MM ASCT was obtained from published
data of direct hospital costs obtained from Nationwide
Inpatient Sample and were converted to Medicare cost-to-
charge ratio. Chemotherapy cost consisted of average
wholesale prices AWP (2008), costs of medical oncology
visits, and cost of managing adverse events. TreeAge Pro
2012 software was used to perform a static decision analysis.
The outcomes were expressed in the units of health utility
values obtained from phase III HOVON trial which measured
quality of life (QoL) using EORTC QLQ-C30 & EuroQoL-5D
scales. Using a Consumer Price Index (CPI), the costs were
converted into 2012 US$. The expected cost of providing
treatment to newly diagnosed MM patients for a period of 5
yrs when they undergo eASCT after induction with IMiD was
$211,869 ($52,454 less than the dASCT) and had an expected
beneﬁt of 2.06 QALYs following treatment (0.19 QALYs more
than dASCT) implying that eASCT is preferred over (domi-
nates) dASCT. Tornado diagram and one-way sensitivity
analysis results indicated that eASCT showed dominance
even if the probability of OSwas lowered to 52.1% (from BC of
65%), or the probability of ORR was lowered to 75.8% (from
BC of 92%), or the probability of 1 year TRM was increased to
11.5% (from BC of 2%).
In absence of a survival beneﬁt, the cost savings of early
ASCT as measured by ICER would favor this approach, and it
would help clinicians, patients, policy makers and third party
payers in decision making. Future prospective studies in MM
ASCT should incorporate economic and QOL components in
the analysis and also focus on the added cost of post-ASCT
maintenance therapies.
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treatment for eligible patients with AL, a disease in which
hematologic response is a key determinant of survival. With
the advent of novel agents the role of SCT for patients with AL
is being questioned, especially given safety concerns. Yet
with appropriate patient selection and the use of risk-
adapted SCT (RA-SCT), treatment-related mortality (TRM)
improved. (Br J Haem 2007;139:224; Bone Marrow Trans-
plantation 2011; 46:970) Beginning in 2002, we showed in 2
consecutive phase II trials that following RA-SCT patients can
safely receive consolidation with thalidomide and dexa-
methasone (TD) or bortezomib and D (BD), with the goal of
improving hematologic response thereby extending overall
survival (OS). (Br J Haem 2007;139:224; Amyloid
2010;17:80a) Consolidation was administered for patients
achieving less than a complete response (CR). We now
describe the outcomes of all patients with AL who under-
went RA-SCT at Memorial Sloan-Kettering Cancer Center
(MSKCC) since the year 2000.
Methods:Weperformeda retrospective study toassess theOS
of all patients who underwent SCT for a diagnosis of AL
conﬁrmed at MSKCC. Patients who had >2 major organs
involved, NYHA class III or greater CHF, critical arrhythmias or
cardiac syncopewere ineligible for SCT.OSwascalculated from
transplant to date of death or last follow up. Median survival
was estimated by Kaplan Meier methods. Log-rank test was
used to determine whether survival functions differed by
covariates of interest. Cumulative incidence functionwas used
to estimate the incidence of cause-speciﬁc mortality.
Results: A total of 151 patients underwent RA-SCT between
February 2000 and June 2011; three lost to follow-up are
excluded from this analysis. Of the remaining 148 patients
21%, 52% and 34% received RA-SCTat 100,140 and 200mg/m2
of melphalan respectively based on age, renal function and
cardiac involvement.(Blood 2002; 99: 4276) Five patients
died within 100 days of SCT (TRM 3.4%). At a median follow
up of 6.7 years, the median OS for all patients is 11.1 years
(95% CI, 7.32 - not reached-NR) (Figure 1), and for patients
who received MEL 100, 140 or 200 is 4.4 (95% CI, 2.7 e 6.3),
NR and 11 years (95% CI, 8.2 e NR) respectively (P  0.01).
Cumulative incidence of disease related mortality at 2 years
is 5.5%, and subsequently the rate of death from other
causes exceeds that due to AL.
Conclusions: RA-SCT for appropriately selected patients is
safe and is associated with excellent long-term survival.
Consolidation with novel agents may improve survival
followingRA-SCTand likelyaccounts for the similarOS seen in
patients who received MEL 140 and 200. In the era of novel
agents available for post-SCT consolidation, RA-SCT is an
effective and important initial treatment for patients with AL.
Figure 1. Survival from SCT.
